Valuation: Axsome Therapeutics, Inc.

Market Cap 10.76B 9.22B 8.63B 7.89B 14.88B 1,030B 15.04B 102B 39.69B 517B 40.4B 39.52B 1,712B P/E 2026 *
-76.8x
P/E 2027 * 44.6x
Enterprise Value 10.6B 9.09B 8.5B 7.77B 14.67B 1,015B 14.82B 101B 39.11B 510B 39.81B 38.95B 1,687B EV / Sales 2026 *
11x
EV / Sales 2027 * 6.61x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day-1.14%
1 week-5.03%
Current month-5.78%
1 month-14.77%
3 months-12.96%
6 months+20.86%
Current year+12.46%
1 week 205.08
Extreme 205.085
222.46
1 month 205.08
Extreme 205.085
245.5
Current year 152.28
Extreme 152.28
260.19
1 year 112.9
Extreme 112.9
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 12/01/2012
Director of Finance/CFO 51 16/05/2018
Chief Operating Officer 42 01/04/2014
Director TitleAgeSince
Chairman 57 12/01/2012
Director/Board Member 64 01/12/2014
Director/Board Member 58 01/12/2014
Date Insider Type Main position Quantity % Market Cap.
06/08/26 Fiscal year

Chief Executive Officer

13,980 0.0272%
01/07/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
05/06/26 Free

Director

1,721 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%-5.03%+73.32%+172.41% 10.76B
-0.66%+2.80%+40.55%-0.33% 82.73B
-4.30%+115.47%+412.13%+23.29% 55.45B
+2.68%+10.02%-19.76%-34.08% 57.94B
+1.42%+1.61%-0.67%+34.08% 52.57B
+0.59%+1.84%+10.10%+170.94% 48.94B
+0.62%+4.29%+56.57%-16.88% 32.23B
+0.13%+3.63%+50.49%+99.25% 25.94B
+0.60%+3.57%+0.15%+196.15% 22.1B
+1.44%-1.46%+57.75%+106.78% 16.55B
Average +0.13%+15.48%+68.06%+75.16% 40.52B
Weighted average by Cap. +0.03%+21.28%+75.03%+47.97%

Financials

2026 *2027 *
Net sales 966M 828M 775M 708M 1.34B 92.52B 1.35B 9.17B 3.56B 46.46B 3.63B 3.55B 154B 1.56B 1.34B 1.25B 1.14B 2.16B 150B 2.18B 14.82B 5.76B 75.11B 5.87B 5.74B 249B
Net income -140M -120M -113M -103M -194M -13.44B -196M -1.33B -518M -6.75B -527M -515M -22.32B 255M 219M 205M 187M 353M 24.45B 357M 2.42B 942M 12.28B 959M 938M 40.62B
Net Debt -156M -134M -125M -115M -216M -14.98B -219M -1.48B -577M -7.52B -588M -575M -24.89B -435M -373M -349M -319M -602M -41.68B -609M -4.13B -1.61B -20.93B -1.63B -1.6B -69.25B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
24/08/26 $205.40 -1.14% 293,225
21/08/26 $207.77 -0.12% 734,950
20/08/26 $208.03 -4.66% 620,926
19/08/26 $218.20 +1.16% 572,114
18/08/26 $215.69 -0.27% 506,353
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
205.40USD
Average target price
285.42USD
Spread / Average Target
+38.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock